[1] Chamberlain M C. Glioblastoma in the elderly[J]. Current Understanding
and Treatment of Gliomas, 2015,12:159-170.
[2] Neagu M R, Huang R Y, Reardon D A, et al. How treatment monitoring is influencing treatment decisions in glioblastomas[J].Current Treatment Options in Neurology,2015,17(4):343.
[3] Hu Q, Gao X, Kang T, et al. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels[J]. Biomaterials,2013,34(37):9496.
[4] Neagu M R, Manguso R T, Pope H, et al. Abstract 417: Defining molecular mechanisms of resistance to glioblastoma immunity using a novel CRISPR/Cas9 in vivo loss-of-function screening platform[J]. Cancer Research,2017,77(13 Supplement):417.
[5] SHEN W,HAN Y,HUANG B,et al.Micro RNA-483-3p inhibits
extracellular matrix production by targeting smad4 in human trabecular
meshwork cells[J]. Invest O phthalmol V is Sci,2015,56(13):8419-
8427.
[6] 姬海宁,辛彦,肖玉平. 血管生成拟态研究进展[J]. 中华肿瘤防治杂志,2011,18 (27):1736-1739.
[7] 苏敏,张玉泉,黄华. HIF-1α、MMP-2在卵巢癌中的表达及其与血管生成拟态的关系[J]. 现代妇产科进展,2011,20(2):83-87.
[8] 郑旭. 肺肉瘤样癌中血管生成拟态的形成及其与上皮间充质转化的关系[D]. 天津:天津医科大学,2013.
[9] Lu, Xin-Sui, Chun-Yan, et al. Contribution of the PI3K/MMPs/Ln-5 gamma 2 and EphA2/FAK/Paxillin; signaling pathways to tumor growth and vasculogenic mimicry of; gallbladder carcinomas[J]. International Journal of Oncology,2013,42(6):2103-2115.
[10] Lu X S, Sun W, Ge C Y, et al. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas[J]. International Journal of Oncology,2013,42(6):2123-2125.
|